BI wants to 'own' lung therapy space as India-priced afatinib debuts
This article was originally published in Scrip
"We want to own the lung cancer therapy space," is how Boehringer Ingelheim (BI) India's managing director Sharad Tyagi refers to the family-owned German multinational's ambitions in the segment with the introduction of its first oncology product, afatinib, on the domestic market.
You may also be interested in...
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.